Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016016766) A PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM OR ITS SALT THEREOF
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

A PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM OR ITS

SALT THEREOF

Field of Invention

The present invention relates to a process for the preparation of stable Isavuconazonium or its salt thereof. In particular of the present invention relates to process for the preparing of isavuconazonium sulfate, Isavuconazonium iodide hydrochloride and Boc -protected isavuconazonium iodide has purity more than 90%. The process is directed to preparation of solid amorphous form of isavuconazonium sulfate, isavuconazonium iodide hydrochloride and Boc -protected isavuconazonium iodide. The present invention process of Isavuconazonium or its salt thereof is industrially feasible, simple and cost effective to manufacture of isavuconazonium sulfate with the higher purity and better yield.

Background of the invention

Isavuconazonium sulfate is chemically known l-[[N-methyl-N-3-[(methylamino) acetoxymethyl]pyridin-2-yl] carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl)thiazol-2-yl]butyl]-lH-[l,2,4]-triazo-4-ium Sulfate and is structurally represented by formula (I):


Formula I

Isavuconazonium sulfate (BAL8557) is indicated for the treatment of antifungal infection. Isavuconazonium sulfate is a prodrug of Isavuconazole (BAL4815), which is chemically known 4-{2-[(lR,2R)-(2,5-Difluorophenyl)-2-hydroxy-l-methyl-3-(lH-l ,2,4-triazol-l-yl)propyl]-l ,3-thiazol-4-yl}benzonitrile compound of Formula II


Formula II

US Ppatent No. 6,812,238 (referred to herein as '238); 7,189,858 (referred to herein as '858); 7,459,561 (referred to herein as '561) describe Isavuconazonium and its process for the preparation thereof.

The US Pat. '238 patent describes the process of preparation of Isavuconazonium chloride hydrochloride.

The US Pat. '238 described the process for the Isavuconazonium chloride hydrochloride, involves the condensation of Isavuconazole and [N-methyl-N-3((tert-butoxycarbonyl methylamino) acetoxymethyl) pyridine-2-yl]carbamic acid 1 -chloro-ethyl ester. The prior art reported process require almost 15-16 hours, whereas the present invention process requires only 8-10 hours. Inter alia prior art reported process requires too many step to prepare isavuconazonium sulfate, whereas the present invention process requires fewer steps.

Moreover, the US Pat. '238 describes the process for the preparation Isavuconazonium hydrochloride, which may be used as the key intermediate for the synthesis of isavuconazonium sulfate, compound of formula I. There are several drawbacks in the said process, which includes the use of anionic resin to prepare Isavuconazonium chloride hydrochloride, consequently it requires multiple time lyophilization, which makes the said prior art process industrially, not feasible.

The inventors of the present invention surprisingly found that Isavuconazonium or a pharmaceutically acceptable salt thereof in yield and purity could be prepared by using substantially pure intermediates in suitable solvent.

Thus, an object of the present invention is to provide simple, cost effective and industrially feasible processes for manufacture of isavuconazonium sulfate. Inventors of the present invention surprisingly found that isavuconazonium sulfate prepared from isavuconazonium iodide hydrochloride, provides enhanced yield as well as purity.

Summary of the Invention

The present invention provides a solid amorphous form of isavuconazonium sulfate, compound of Formula


Formula I

The present invention provides the process for the preparation of a solid amorphous form of isavuconazonium sulfate compound of Formula I, which includes contacting isavuconazonium iodide hydrochloride compound of Formula IA with anion exchange resin in the suitable solvent and followed by isolation of isavuconazonium sulfate compound of Formula I in the suitable solvent.

In another aspect, the present invention provides isavuconazonium sulfate compound of Formula I, has purity more than 94%, when measured by HPLC.

The present invention also provides a solid amorphous form of isavuconazonium iodide hydrochloride, compound of Formula IA,


Formula IA

In another aspect, the present invention provides isavuconazonium iodide hydrochloride compound of Formula IA, has purity more than 90%, when measured by HPLC.

The present invention provides the process for the preparation of a solid amorphous form of isavuconazonium iodide hydrochloride compound of Formula IA, which includes steps of reacting isavuconazole compound of formula (II) or salt thereof with [N-methyl-N-3((tert-butoxycarbonyl methylamino) acetoxymethyl) pyridine-2-yl]carbamic acid 1-chloro-ethyl ester or salt thereof compound of formula (III) in presence of iodide salt, in the suitable solvent to obtain compound of Boc -protected isavuconazonium iodide compound of formula (IV). Deprotection of Boc -protected isavuconazonium iodide compound of formula (IV) with hydrochloric acid in suitable solvent to obtain isavuconazonium iodide hydrochloride compound of Formula IA.


Formula (III) Formula (III)

In another aspect, the present invention provides a solid amorphous form of Boc-isavuconazonium iodide com ound of formula (IV)


Formula IV

In another aspect, the present invention provides solid amorphous form of Boc-isavuconazonium iodide, has purity more than 90%, when measured by HPLC.

Brief Description of the Drawings

Figure 1 shows an illustrative example of X-ray powder diffraction pattern of solid amorphous form of isavuconazonium sulfate.

Figure 2 shows an illustrative example of differential scanning calorimetry thermogram of solid amorphous form of isavuconazonium sulfate.

Figure 3 shows an illustrative example of thermogravimetric analysis curve of solid amorphous form of isavuconazonium sulfate

Figure 4 shows an illustrative example of X-ray powder diffraction pattern of solid amorphous form of isavuconazonium iodide hydrochloride.

Figure 5 shows an illustrative example of differential scanning calorimetry thermogram of solid amorphous form of isavuconazonium iodide hydrochloride.

Figure 6 shows an illustrative example of thermogravimetric analysis curve of solid amorphous form of isavuconazonium iodide hydrochloride

Figure 7 shows an illustrative example of X-ray powder diffraction pattern of solid amorphous form of Boc-isavuconazonium iodide.

Figure 8 shows an illustrative example of differential scanning calorimetry thermogram of solid amorphous form of Boc-isavuconazonium iodide.

Figure 9 shows an illustrative example of thermogravimetric analysis curve of solid amorphous form of Boc-isavuconazonium iodide

Description of the Invention

For purposes of the present invention, the following terms are defined below.

The X-ray diffraction powder patterns of the present invention were obtained using a Bruker or PANalytical export Pro Powder X-ray Diffractometer at Cu Ka radiation, has the wavelength 1.54 A.

As used herein, the term "reference standard" refers to a compound that may be used both for quantitative and qualitative analysis of an active pharmaceutical ingredient. A reference marker" is used only for qualitative analysis, while a reference standard may be used for quantitative or qualitative analysis, or both. Hence, a reference marker is a subset of a reference standard, and is included within the definition of a reference standard.

In one aspect of the present invention provides a solid amorphous form of isavuconazonium sulfate, compound of Formula I,

Formula I

In another aspect, the present invention provides a solid amorphous form of isavuconazonium sulfate is characterized by its X-ray powder diffraction pattern substantially as shown in Figure 1, differential scanning calorimetry thermogram as shown in Figure 2 and Thermogavimetric Analysis (TGA) as shown in Figure 3.

The solid amorphous form of isavuconazonium sulfate obtained according to present invention was stored at 25 °C for a period of 3 months and no conversion in the polymorphic form was observed.

In another aspect, the present invention provides a solid amorphous form isavuconazonium sulfate, compound of Formula I, has purity more than 94 % by as measured HPLC.

In one of the embodiment the isavuconazonium Sulfate obtained by the process of present invention shown stability under standard condition of stability as described in United States Pharmacopoeia 2014.

In another aspect, the present invention provides a process for the preparation of isavuconazonium sulfate, compound of Formula I,


Formula I

which includes steps of;

a) contacting isavuconazonium iodide hydrochloride compound of Formula IA


Formula IA

with anion exchange resin in the suitable solvent,

b) isolating isavuconazonium sulfate in the suitable solvent.

Suitable solvent is selected from the group comprising one or more of alcohol, halogenated solvent, acetates, ether, hydrocarbon, water or mixture thereof. The alcohol such as methanol, ethanol, isopropyl alcohol and the like; the halogenated solvent such dichlorome thane; the ether such as methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether and the like; the amides such as dimethyl acetamide and dimethyl formamide and the like; the acetate such as ethyl acetate, propyl acetate, butyl acetate and the like; hydrocarbon such as toluene, n-hexane, benzene, heptane and the like.

The anion exchange resin includes is selected from the group comprising Diaion™ SA10A, Diaion™ SA11A, Diaion™ SA12A, Diaion™ NSA100, Diaion™ PA308, PA306, Amberjet 4000 CI, Amberjet 4400 CI and Amberjet 4600 CI.

In one aspect, the present invention provides a solid amorphous form of isavuconazonium iodide hydrochloride, compound of Formula IA.


Formula IA

In another aspect, the present invention provides isavuconazonium iodide hydrochloride, has purity more than 90 %, as measured HPLC.

In another aspect, the present invention provides a solid amorphous form of isavuconazonium iodide hydrochloride is characterized by its X-ray powder diffraction pattern substantially as shown in Figure 4, differential scanning calorimetry thermogram as shown in Figure 5 and Thermogavimetric Analysis (TGA) as shown in Figure 6.

The solid amorphous form of isavuconazonium iodide hydrochloride obtained according to present invention was stored at 25 °C for a period of 3 months and no conversion in the polymorphic form was observed.

In one aspect, the present invention provides a solid amorphous form of Boc-isavuconazonium iodide compound of formula (IV)


Formula IV

In another aspect, the present invention provides a solid amorphous form of Boc-isavuconazonium iodide is characterized by its X-ray powder diffraction pattern substantially as shown in Figure 7, differential scanning calorimetry thermogram as shown in Figure 8 and Thermogavimetric Analysis (TGA) as shown in Figure 9.

The solid amorphous form of Boc -isavuconazonium iodide obtained according to present invention was stored at 25 °C for a period of 3 months and no conversion in the polymorphic form was observed.

In another aspect, the present invention provides a solid amorphous form of Boc-isavuconazonium iodide, has purity more than 90 %, as measured HPLC.

In another aspect, the present invention provides a process for the preparation of isavuconazonium iodide hydrochloride compound of Formula IA,


Formula IA

which includes steps of

a) reacting isavuconazole comp r salt thereof


Formula II

with [N-methyl-N-3((tert-butoxycarbonylmethylamino)acetoxymethyl)pyridine- 2-yl] carbamic acid 1 -chloro-ethyl ester or salt thereof compound of formula (III)


Formula III

in presence of iodide salt, in the suitable solvent to obtain Boc -protected isavuconazonium iodide com ound of formula (IV)


Formula IV

b) deprotecting Boc -protected isavuconazonium iodide compound of formula (IV) with hydrochloric acid in suitable solvent to obtain isavuconazonium iodide hydrochloride compound of Formula IA.

Suitable solvent used in the step (a) is selected from the group comprising one or more of nitrile, ether, amides, alcohol, acetates, hydrocarbon, water or mixture thereof. The nitriles such as acetonitrile and propionitrile and the like; the ether such as methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, dioxane and the like; the amides such as dimethyl acetamide and dimethyl formamide and the like; the alcohol such as methanol, ethanol, isopropyl alcohol and the like; the acetate such as ethyl acetate, propyl acetate, butyl acetate and the like; hydrocarbon such as toluene, n-hexane, benzene, heptane and the like;

Suitable solvent used in the step (b) is selected from the group comprising one or more of acetates, alcohols, amides, ether, chlorinated solvents, water or mixture thereof. The acetate such as ethyl acetate, propyl acetate, butyl acetate and the like; the alcohol such as methanol, ethanol, isopropyl alcohol and the like; the ether such as methyl tert-butyl ether, ethyl tert-butyl ether, diethyl ether, di-tert-butyl ether, dioxane and the like; the amides such as dimethyl acetamide and dimethyl formamide and the like; chlorinated solvents such as dichloromethane, chloroform, chlorobenzene and the like.

The used hydrochloric gas is purged in suitable solvent, wherein the percentage of hydrochloric acid in the suitable solvent is 12 to 20 % w/v.

Iodide salt used for the reaction includes but is not limited to potassium iodide and sodium iodide.

The process of the present invention is depicted in the following scheme:

Formula I

Formula-IA

The present invention is further illustrated by the following example, which does not limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present application.

Examples

Example-1: Synthesis of l-[[N-methyl-N-3-[(t-butoxycarbonylmethylamino) acetoxymethyl]pyridin-2-yl]carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3 - [4-(4-cyanophenyl)thiazol-2-yl]butyl] - 1 H-[ 1 ,2,4] -triazo-4-ium iodide

Isavuconazole (20 g) and [N-methyl-N-3((tert-butoxycarbonylmethylamino)acetoxy methyl)pyridine-2-yl]carbamic acid 1 -chloro-ethyl ester (24.7 g) were dissolved in acetonitrile (200ml). The reaction mixture was stirred to add potassium iodide (9.9 g). The reaction mixture was stirred at 47-50°C for 10-13 hour. The reaction mixture was cooled to room temperature. The reaction mass was filtered through celite bed and washed acetonitrile. Residue was concentrated under reduced pressure to give the crude solid product (47.7 g). The crude product was purified by column chromatography to get its pure iodide form (36.5 g).

Yield: 84.5 %

HPLC Purity: 87%

Mass: m/z 817.4 (M- 1)+

Example-2: Synthesis of l-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl] carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl) thiazol-2-yl]butyl]-lH-[l ,2,4]-triazo-4-ium iodide hydrochloride

l-[[N-methyl-N-3-[(t-butoxycarbonylmethylamino)acetoxymethyl]pyridin-2-yl] carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl) thiazol-2-yl]butyl]-lH-[l ,2,4]-triazo-4-ium iodide (36.5 g) was dissolved in ethyl acetate (600 ml). The reaction mixture was cooled to -5 to 0 °C. The ethyl acetate hydrochloride (150 ml) solution was added to reaction mixture. The reaction mixture was stirred for 4-5 hours at room temperature. The reaction mixture was filtered and obtained solid residue washed with ethyl acetate. The solid dried under vacuum at room temperature for 20-24 hrs to give 32.0 gm solid.

Yield: 93 %

HPLC Purity: 86%

Mass: m/z 717.3 (M-HC1- 1)

Example-3: Preparation of Strong anion exchange resin (Sulfate).

Indion GS-300 was treated with aqueous sulfate anion solution and then washed with DM water. It is directly used for sulfate salt.

Example-4: Synthesis of l-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl] carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl) thiazol-2-yl]butyl]-lH-[l ,2,4]-triazo-4-ium Sulfate

Dissolved 10.0 g l-[[N-methyl-N-3-[(methylamino)acetoxymethyl]pyridin-2-yl] carbamoyloxy]ethyl-l-[(2R,3R)-2-(2,5-difluorophenyl)-2-hydroxy-3-[4-(4-cyanophenyl) thiazol-2-yl]butyl]-lH-[l ,2,4]-triazo-4-ium iodide hydrochloride in 200 ml deminerahzed water and 30 ml methanol. The solution was cooled to about 0 to 5°C. The strong anion exchange resin (sulfate) was added to the cooled solution. The reaction mixture was stirred to about 60-80 minutes. The reaction was filtered and washed with 50ml of demineralized water and methylene chloride. The aqueous layer was lyophilized to obtain

(8.0 g) white solid.

Yield: 93 %

HPLC Purity: > 90%

Mass: m/z 717.4 (M- HS04) +